Menu
Theme
Sign In(1) What do earnings, genes, and Brazil have in common? They’re all remarkable. (2) Get ready for a great Q1 reporting season. (3) Q1 earnings growth in high teens expected; analysts see roughly 20% growth in 2Q, 3Q, and 4Q. (4) Analysts have been upping earnings sights dramatically, for Q1 and 2018, across nearly all sectors. (5) Novartis pays up to beef up its gene-editing capabilities with acquisition of AveXis. (6) Brazil’s MSCI Index has stumbled in April as presidential contender Lula heads off to the clinker. (7) A lulu of a buying opportunity?
End of free preview
Ed's complete analysis, every chart linked, and the archive back to 2009.
Individual investor? Ed's QuickTakes are available for personal use at yardeniquicktakes.com →